ABSTRACT
In a parallel-group double-blind study, 142 outpatients with "mixed anxiety/depression" were treated with amoxapine or doxepin for 4 weeks in mean maximum daily dosages of 260 mg and 130 mg, respectively. Patients in both groups improved significantly during treatment as shown by changes in the Hamilton, Zung, Patient Self-Evaluation, and Clinical Global Impressions scales. From 24 to 31 of the 71 subjects receiving amoxapine and 16 to 24 of the 71 receiving doxepin were rated as "unquestionably improved" at the end of the treatment period on these scales. The time to achieve this degree of response was significantly shorter with amoxapine on both the CGI (p = .018) and Hamilton (p = .005) scales. Side effects were roughly comparable with two exceptions: doxepin-treated patients experienced more daytime drowsiness (p less than or equal to .05) and amoxapine-treated patients experienced more constipation (p less than or equal to .01).
Subject(s)
Ambulatory Care , Amoxapine/therapeutic use , Anxiety Disorders/drug therapy , Depressive Disorder/drug therapy , Dibenzoxazepines/therapeutic use , Doxepin/therapeutic use , Adult , Amoxapine/adverse effects , Anxiety Disorders/complications , Anxiety Disorders/psychology , Constipation/chemically induced , Depressive Disorder/complications , Depressive Disorder/psychology , Double-Blind Method , Doxepin/adverse effects , Female , Humans , Male , Personality Inventory , Psychiatric Status Rating Scales , Sleep StagesABSTRACT
A total of 61 moderately to severely depressed outpatients were treated for four weeks with either amoxapine (a dibenzoxapine tricyclic) or amitriptyline. This double blind study showed that amoxapine was as effective as amitriptyline and had an earlier onset of action. Maximum doses used were 300 mg of amoxapine and 150 mg of amitriptyline. Side effects were similar for the two drugs, except for impotence or loss of libido in eight male amoxapine, as against three amitriptyline patients. Laboratory, EKG, and vital signs findings showed no pathological trends.
Subject(s)
Amitriptyline/therapeutic use , Amoxapine/therapeutic use , Bipolar Disorder/drug therapy , Depression/drug therapy , Dibenzoxazepines/therapeutic use , Adolescent , Adult , Aged , Amitriptyline/administration & dosage , Amitriptyline/adverse effects , Amoxapine/administration & dosage , Amoxapine/adverse effects , Double-Blind Method , Drug Evaluation , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Time FactorsSubject(s)
Chlorpromazine/therapeutic use , Phenothiazines/therapeutic use , Piperazines/therapeutic use , Schizophrenia/drug therapy , Tranquilizing Agents/therapeutic use , Acute Disease , Chlorpromazine/adverse effects , Clinical Trials as Topic , Humans , Phenothiazines/adverse effects , Piperazines/adverse effects , Psychiatric Status Rating Scales , Tranquilizing Agents/adverse effectsSubject(s)
Dibenzoxazepines/therapeutic use , Schizophrenia/drug therapy , Tranquilizing Agents/therapeutic use , Catatonia/drug therapy , Clinical Trials as Topic , Dibenzoxazepines/administration & dosage , Female , Humans , Male , Oxazines/adverse effects , Paranoid Disorders/drug therapy , Psychiatric Status Rating Scales , Tranquilizing Agents/administration & dosage , Tranquilizing Agents/adverse effectsSubject(s)
Bipolar Disorder/diagnosis , Schizophrenia/diagnosis , Bipolar Disorder/drug therapy , Diagnosis, Differential , Female , Humans , Interview, Psychological , Lithium/therapeutic use , Male , Personality Inventory , Phenothiazines/therapeutic use , Psychiatric Status Rating Scales , Schizophrenia/drug therapySubject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Depressive Disorder, Major/drug therapy , Imipramine/therapeutic use , Pyridines/therapeutic use , Antidepressive Agents/adverse effects , Arteries , Blood Pressure/drug effects , Clinical Trials as Topic , Female , Humans , Imipramine/adverse effects , Male , Middle Aged , Placebos , Psychological Tests , Pyridines/adverse effectsSubject(s)
Mental Disorders/diagnosis , Psychiatric Status Rating Scales , Adolescent , Adult , Aged , Alcoholism/diagnosis , Analysis of Variance , Depression/diagnosis , Female , Humans , Interview, Psychological , Male , Middle Aged , Neurotic Disorders/diagnosis , Psychotic Disorders/diagnosis , Schizophrenia/diagnosis , Statistics as TopicSubject(s)
Mental Disorders/complications , Substance-Related Disorders/etiology , Adult , Age Factors , Amphetamine , Antisocial Personality Disorder/complications , Antitussive Agents , Barbiturates , Cannabis , Cocaine , Crime , Depression/complications , Euphoria , Female , Glutethimide , Hallucinogens , Hospitalization , Hospitals, Psychiatric , Humans , Lysergic Acid Diethylamide , Male , Morphine Dependence , Motivation , Personality Disorders/complications , Schizophrenia/complications , Sex Factors , TrichloroethyleneSubject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Depressive Disorder, Major/drug therapy , Adult , Aged , Antidepressive Agents/adverse effects , Anxiety/chemically induced , Blood Pressure/drug effects , Constipation/chemically induced , Deglutition Disorders/chemically induced , Female , Headache/chemically induced , Humans , Male , Middle Aged , Nausea/chemically induced , Psychological Tests , Sleep Initiation and Maintenance Disorders/chemically induced , Tremor/chemically inducedABSTRACT
This study was designed to evaluate some of the effects of a new thioxanthene, thiothixene (P-4657B), in 20 male schizophrenic patients recently admitted to Bellevue Hospital. The results of a dosage range trial indicated that at a dosage of approximately 50 mg per day, toxic and side effects as well as therapeutic effects were at their maximum. Parkinsonian reactions (in 17 of 20 patients) with restlessness and akathisia were the most prominent of these effects. Also, activation of psychopathology was observed in six of 20 subjects. Thiothixine did exhibit some antipsychotic activity, but it does not appear to be as valuable as it has been reported to be in chronic schizophrenic patients.
